TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The release of the opioid antagonist takes place in a continuous manner over a period of 30 minutes to 6 hours, preferably 45 minutes to 4.5 hours after the oral administration. The opioid is a full agonist, preferably morphine. The opioid antagonist is an opioid antagonist with an oral bioavailability of 5%. The opioid antagonist is naloxone. The release of the opioid takes place during a period of 0-12 hours, preferably 0-24 hours after the oral administration. The first and the second particles are present in a globular form or at least one particle is present in a globular form. The globular form comprises a core and a coating including at least a polyacrylate- or a methacrylate polymer or Eudragit (RTM: Methyl 2-methylprop-2-enoate) for the controlled release of an active agent. ACTIVITY - Antiaddictive; Analgesic. No biological data given.    MECHANISM OF ACTION - Opioid antagonist.    ADMINISTRATION - Administration of opioid antagonist and opioid is in a ratio of less than 1:10, preferably 1:100, twice, preferably once in a day, via per-orally in a dosage form of capsule, preferably a hard-gelatin capsule or a sachet. Administration of opioid for the treatment of opioid addiction is 30 mg, 60 mg or 200 mg (preferred) and for pain-therapy is 30 mg or 60 mg (all claimed).    EXAMPLE - Typical composition comprised of a mixture of: morphine in globular form (film coated with a suspension of morphine sulfate, Kollidon K 25 (RTM: Povidon) and titanium dioxide in purified water, where the globular form was first film-coated with a coating suspension of talc and Eudragit FS 30 D (RTM: Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid)) in purified water, and then the globular form was film-coated with a retarding coating suspension of hypromellose, polysorbate 80, talc, titanium dioxide, Eudragit NE 30 D (RTM: Poly(ethyl acrylate-co-methyl methacrylate)) and Eudragit FS 30 D (RTM: Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid)) and then a dispersion of Aerosil 200 (RTM: Highly dispersed amorphous silica) was sprayed over the above layer); and a naloxone in globular form (film coated with a suspension of naloxone hydrochloride dihydrate, Kollidon K 25 (RTM: Povidon) and titanium dioxide in purified water, where the globular form was film-coated with a retarding coating suspension of hypromellose, polysorbate 80, talc, titanium dioxide, Eudragit NE 30 D (RTM: Poly(ethyl acrylate-co-methyl methacrylate)) and Eudragit FS 30 D (RTM: Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid)) and then a dispersion of Aerosil 200 (RTM: Highly dispersed amorphous silica) was sprayed over the above layer)).